Project description:The National Institute of Neurological Disorders and Stroke (NINDS) Human Genetics Resource Center: DNA and Cell Line Repository (the NINDS Repository): Cerebrovascular Disease/Stroke Study
Project description:The National Institute of Neurological Disorders and Stroke (NINDS) Human Genetics Resource Center: DNA and Cell Line Repository (the NINDS Repository): Cerebrovascular Disease/Stroke Study
Project description:<p>The National Institute of Neurological Disorders and Stroke (NINDS) Human Genetics Resource Center: DNA and Cell Line Repository
(<a href="http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10">the NINDS Repository)</a>, banks phenotypic data and biological
samples, including from individuals with cerebrovascular disease, in order to facilitate gene discovery in neurological disorders.
Those samples are used in a number of studies, and genotyping data from studies using this resource are encouraged to be shared
via dbGaP. Many studies have already shared data in this fashion, which in turn, can be linked back to the biologicals banked at the
NINDS Repository.
</p>
<p>Stroke is the third leading cause of death in the United States, and is an acute neurological event leading to death of neural
tissues. Although the majority of strokes are ischemic strokes, meaning there is oxygen deprivation to the brain, almost 20% of strokes
are hemorrhagic, resulting from bleeding into the brain. Samples available in
<a href="http://ccr.coriell.org/Sections/Collections/NINDS/Cerebrovascular.aspx?PgId=190&coll=ND">cerebrovascular disease</a>
in the NINDS Repository, include but are not limited to those from individuals affected with the following: ischemic stroke,
hemorrhagic stroke, intracranial aneurysm (both ruptured and unruptured), transient ischemic attack, arteriovenous malformations,
and others. Many studies contribute to the NINDS Repository collection in an ongoing manner and others are being added regularly.
These studies include samples from the Vitamin Intervention for Stroke Prevention (VISP) study, the Ischemic Stroke Genetics Study
(ISGS), the Familial Intracranial Aneurysm study, and many others.
</p>
<p>There is also an associated Control collection (see <a href="./study.cgi?id=phs000004">dbGaP</a>
and <a href="http://ccr.coriell.org/Sections/Collections/NINDS/Population.aspx?PgId=194&coll=ND">
Coriell</a>). Others studies may use cases from the NINDS
repository, controls from the NINDS repository, as well as cases, and controls, from other sources. A subset of subjects from
The National Institute of Neurological Disorders and Stroke (NINDS) Human Genetics Resource Center: DNA and Cell Line Repository
(the NINDS Repository): Cerebrovascular Disease/Stroke Study was utilized in the <a href="./study.cgi?id=phs000102">Ischemic Stroke
Genetics Study (ISGS)</a> study.
</p>
Project description:This work presents the discovery of genes that are dysregulated in patients with Type I and Type III Gaucher Disease. It provides insight into the unique pathogenesis of these phenotypes, improved diagnostic accuracy and potential novel therapies for these patients. Control and patient fibroblast cultures were established from full-thickness, skin biopsies obtained under a protocol approved by the IRB of the National Institute of Neurological Disorders and Stroke. Patient cultures were homoallelic for either the N370S mutation (non-neuronopathic, Gaucher Disease Type I, n=5), the L444P mutation (neuronopathic, Gaucher Disease Type III, n=5), or Wild-Type (Control, n=4).
Project description:<p>The third leading cause of death in the United States, stroke is an acute neurological event leading to death of neural tissues.
Although the majority of strokes are ischemic strokes, meaning there is oxygen deprivation to the brain, almost 20% of strokes are
hemorrhagic, resulting from bleeding into the brain. Stroke is a complex disorder and likely multigenic in nature, resulting from
a combination of genetic and environmental factors. These well characterized risk factors that contribute to the incidence of stroke
include hypertension, cardiac disease, sickle cell disease, hyperhomocysteinemia, family history of stroke and smoking.
</p>
<p>ISGS aim is to perform a prospective genetic association study of ischemic stroke focusing on the hemostatic system. ISGS
is a 5-center case-control study of first-ever ischemic stroke cases and concurrent controls individually matched for age,
sex and recruitment site.
</p>
<p>This data includes that from subjects both banked in the <a href="http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10">
NINDS repository</a> with biologicals publicly available, and those whose samples are not banked/not available.
</p>
<!-- <p><b>Important links to apply for individual-level data</b>
<ol>
<li><a href="http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?view_pdf&stacc=phs000102.v1.p1" target="_blank">Data Use Certification Requirements (DUC)</a></li>
<li><a href="http://view.ncbi.nlm.nih.gov/dbgap-controlled" target="_blank">Apply here for controlled access to individual level data</a></li>
<li><a href="GetPdf.cgi?id=phd000582" target="_blank">Participant Protection Policy FAQ</a></li>
</ol>
</p> -->
<p>This study utilized the <a href="./study.cgi?id=phs000005">NINDS Repository Cerebrovascular/Stroke Study</a>,
and <a href="./study.cgi?id=phs000004">neurologically normal controls</a> from the sample population which are banked in the National
Institute of Neurological Disorders and Stroke (NINDS Repository) collection for a first stage whole genome analysis.</p>
Project description:<p>The third leading cause of death in the United States, stroke is an acute neurological event leading to death of neural tissues.
Although the majority of strokes are ischemic strokes, meaning there is oxygen deprivation to the brain, almost 20% of strokes are
hemorrhagic, resulting from bleeding into the brain. Stroke is a complex disorder and likely multigenic in nature, resulting from
a combination of genetic and environmental factors. These well characterized risk factors that contribute to the incidence of stroke
include hypertension, cardiac disease, sickle cell disease, hyperhomocysteinemia, family history of stroke and smoking.
</p>
<p>ISGS aim is to perform a prospective genetic association study of ischemic stroke focusing on the hemostatic system. ISGS
is a 5-center case-control study of first-ever ischemic stroke cases and concurrent controls individually matched for age,
sex and recruitment site.
</p>
<p>This data includes that from subjects both banked in the <a href="http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10">
NINDS repository</a> with biologicals publicly available, and those whose samples are not banked/not available.
</p>
<!-- <p><b>Important links to apply for individual-level data</b>
<ol>
<li><a href="http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?view_pdf&stacc=phs000102.v1.p1" target="_blank">Data Use Certification Requirements (DUC)</a></li>
<li><a href="http://view.ncbi.nlm.nih.gov/dbgap-controlled" target="_blank">Apply here for controlled access to individual level data</a></li>
<li><a href="GetPdf.cgi?id=phd000582" target="_blank">Participant Protection Policy FAQ</a></li>
</ol>
</p> -->
<p>This study utilized the <a href="./study.cgi?id=phs000005">NINDS Repository Cerebrovascular/Stroke Study</a>,
and <a href="./study.cgi?id=phs000004">neurologically normal controls</a> from the sample population which are banked in the National
Institute of Neurological Disorders and Stroke (NINDS Repository) collection for a first stage whole genome analysis.</p>
Project description:<p>The National Institute of Neurological Disorders and Stroke (NINDS) Human Genetics Resource Center: DNA and Cell Line Repository (<a href="http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10">the NINDS Repository</a>), banks phenotypic data and biological samples, including from individuals with motor neuron disease, in order to facilitate gene discovery in neurological disorders. Those samples are used in a number of studies, and genotyping data from studies using this resource are encouraged to be shared via dbGaP. Many studies have already shared data in this fashion, which in turn, can be linked back to the biologicals banked at the NINDS Repository. </p> <p>Motor Neuron Disease is characterized by selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In Amyotrophic Lateral Sclerosis (ALS), there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes, the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy, the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation (Adams et al, Principles of Neurology, 6th ed, p 1089). The Motor Neuron Disease Collection of DNA and cell lines in the NINDS Repository is largely Amyotrophic Lateral Sclerosis cases (others include progressive muscular atrophy, primary lateral sclerosis, progressive bulbar palsy, Kennedy's disease). Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). Although ALS is the most common MND, it is still a relatively rare disease with an incidence of around 1.6 per 100,000 in the United States. It is currently incurable and treatment is largely limited to supportive care. Family history is associated with an increased risk of ALS, and many Mendelian causes have been discovered (including SOD1). However, most forms of the disease are not obviously familial. It is suspected that the sporadic forms of neurodegenerative disorders are caused by multiple genetic variants that individually make relatively weak contributions to risk. </p> <p>There is also an associated Control collection (see <a href="./study.cgi?study_id=phs000004.v1.p1">dbGaP</a> and <a href="http://ccr.coriell.org/Sections/Collections/NINDS/Population.aspx?PgId=194&coll=ND"> Coriell</a>). Studies in motor Neuron Disease may use cases from the NINDS repository, controls from the NINDS repository, as well as cases, and controls, from other sources. A subset of subjects from The National Institute of Neurological Disorders and Stroke (NINDS) Human Genetics Resource Center: DNA and Cell Line Repository (the NINDS Repository): Motor Neuron/Amyotrophic Lateral Sclerosis (ALS) Study was utilized in the <a href="./study.cgi?id=phs000101">Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data</a> study. </p> <p><b>Note: The publication <a href="http://www.ncbi.nlm.nih.gov/pubmed/19193627" target="_blank">Chio et al., 2009</a> states that "Raw sample-level genotype data from the initial GWAS study ... are available for download through the dbGAP portal (<a href="./study.cgi?id=phs000006" target="_blank">phs000006.v1.p1</a>)". Instead, please follow this link: <a href="./study.cgi?study_id=phs000101.v1.p1">phs000101.v1.p1</a>.</b></p>
Project description:<p>This study utilized the well characterized collection of North American Caucasians with Parkinson's disease, and neurologically normal controls from the sample population which are banked in the National Institute of Neurological Disorders and Stroke (NINDS Repository) collection. Two sub-studies are included, in sub-study NINDS-Genome-Wide Genotyping in Parkinson's Disease, genome-wide, single nucleotide polymorphism (SNP) genotyping of these publicly available samples was originally done in 267 Parkinson's disease patients and 270 controls, and this has been extended to include genome wide genotyping in 939 Parkinson's disease cases and 802 controls; in sub-study NINDS-Exome Sequencing in Parkinson's Disease, genome wide exome DNA sequencing was done in 618 Parkinson's disease samples deposited in Coriell NINDS repository. The DNA comes from a mixture of blood, and from cell lines (lymphoblast cell lines) derived from blood. The GWAS data and exome sequencing data was generated and provided by the laboratory of Neurogenetics lead by Dr. Andrew Singleton, NIA, and Dr. John Hardy, a former chief at NIA, NIH.</p> <p><b>The NINDS Parkinson's Disease Cohort study is utilized in the following dbGaP individual studies.</b> To view genotypes, whole exome sequencing, and derived variables collected in these individual studies, please click on the following individual studies below or in the "Sub-studies" box located on the right hand side of this top-level study page <a href="study.cgi?study_id=phs001172">phs001172</a> NINDS Parkinson's Disease Cohort study. <ul> <li><a href="study.cgi?study_id=phs000089">phs000089</a> PD GWAS</li> <li><a href="study.cgi?study_id=phs001103">phs001103</a> PD Exome</li> </ul> </p>
Project description:The Genotype-Tissue Expression (GTEx) project is a collaborative effort that aims to identify correlations between genotype and tissue-specific gene expression levels that will help identify regions of the genome that influence whether and how much a gene is expressed. GTEx is funded through the Common Fund, and managed by the NIH Office of the Director in partnership with the National Human Genome Research Institute, National Institute of Mental Health, the National Cancer Institute, the National Center for Biotechnology Information at the National Library of Medicine, the National Heart, Lung and Blood Institute, the National Institute on Drug Abuse, and the National Institute of Neurological Diseases and Stroke, all part of NIH. This series of 837 samples represents multiple tissues collected from 102 GTEX donors and 1 control cell line. In total, 30 tissue sites are represented including Adipose, Artery, Heart, Lung, Whole Blood, Muscle, Skin, and 11 brain subregions. RNA-seq expression data, robust clinical data, pathological annotations, and genotypes are also available for these samples from dbGaP (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000424.v2.p1) and the GTEx portal (www.broadinstitute.org/gtex). While GTEx is no longer generating Affymetrix expression data, donor enrollment continues and is expected to reach 1,000 by the end of 2015. Updates to the GTEx data in dbGaP and the GTEx Portal will be made periodically. contributor: GTEx Laboratory, Data Analysis, and Coordinating Center (LDACC) contributor: The Broad Institute of MIT and Harvard (LDACC PIs: Kristin Ardlie and Gaddy Getz)